期刊文献+

NVP-BEZ235逆转伯基特淋巴瘤RAJI细胞阿霉素耐药的研究

Reversal Effect of NVP-BEZ235 on Doxorubicin-Resistance in Burkitt Lymphoma RAJI Cell Line
下载PDF
导出
摘要 目的:研究NVP-BEZ23对耐阿霉素细胞株RAJI/DOX的逆转耐药作用。方法:利用浓度梯度法诱导耐阿霉素细胞株RAJI/DOX;Western blot测定各组细胞Pgp、p-AKT、p-mTOR蛋白水平;MTT法检测细胞抑制率,SPSS软件测定IC50。结果:成功诱导出耐阿霉素细胞株RAJI/DOX。耐阿霉素细胞株RAJI/DOX中Pgp、p-AKT、p-mTOR蛋白水平高于亲本细胞RAJI。NVP-BEZ235可引起耐阿霉素细胞株RAJI/DOX中p-AKT、p-mTOR蛋白水平下降。NVP-BEZ235能够抑制耐阿霉素细胞株RAJI/DOX增殖,与阿霉素具有协同作用。结论:PI3K/AKT/mTOR通道在耐阿霉素伯基特淋巴瘤细胞中进一步活化;NVP-BEZ235通过抑制PI3K/AKT/mTOR信号通道活化,能够与阿霉素协同抑制伯基特淋巴瘤耐药细胞,逆转伯基特淋巴瘤耐药细胞对阿霉素的耐药性。 Objective:To study the reversal effect of NVP-BEZ235 on doxorubicin resistance in Burkitt lymphoma RAJI cell line.Methods:The doxorubicin-resistant cell line was induced by treating RAJI cells with a concentration gradient of doxorubicin.The levels of Pgp,p-AKT,and p-mTOR in cells were detected by Western blot.Cell viability was detected by MTT assay.IC50 was computed by SPSS.Results:The doxorubicin-resistant Burkitt lymphoma cell line,RAJI/DOX,was established successfully.The expression of Pgp and the phosphorylation levels of AKT and mTOR in RAJI/DOX cell line were both higher than those in RAJI cell line.NVP-BEZ235 downregulated the phosphorylation levels of AKT and mTOR in RAJI/DOX cell line.NVP-BEZ235 inhibited the proliferation of RAJI/DOX cell line,and the effect was obvious when it was cooperated with doxorubicin.Conclusion:The constitutive activation of PI3K/AKT/mTOR pathway of RAJI/DOX cell line was more serious than RAJI cell line.NVP-BEZ235 reversed doxorubicin resistance of RAJI/DOX cell line by inhibiting the PI3K/AKT/mTOR signal pathway.
作者 李纯团 朱雄鹏 王少雄 彭群艺 郑艳 刘生全 卢旭东 王永彬 翁丹 王丹 LI Chun-Tuan;ZHU Xiong-Peng;WANG Shao-Xiong;PENG Qun-Yi;ZHENG Yan;LIU Sheng-Quan;LU Xu-Dong;WANG Yong-Shan;WENG Dan;WANG Dan(Department of Hematology,The First Hospital of Quanzhou Affiliated to Fujian Medical Uinversity,Quanzhou 362200,Fujian Province,China;Department of Clinical Medicine,Fujian Medical University,Fuzhou 350004,Fujian Province,China)
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2024年第2期476-482,共7页 Journal of Experimental Hematology
基金 福建省自然科学基金项目(2022J011461)。
关键词 NVP-BEZ235 伯基特淋巴瘤 阿霉素耐药 逆转 NVP-BEZ235 Burkitt lymphoma doxorubicin-resistance reversal effect
  • 相关文献

参考文献2

二级参考文献22

  • 1Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations [ J 1. Nat Rev Cancer, 2009, 9 (8): 550- 562.
  • 2Maity A, Bernhard EJ. Modulating tumor vasculature through signaling inhibition to improve cytotoxie therapy [J]. Cancer Res, 2010, 70(6) : 2141-2145.
  • 3De Benedetti A, Graft JR. elF-4E expression and its role in malignancies and metastases [ J ]. Oneogene, 2004, 23 ( 18 ) : 3189- 3199.
  • 4Harris NL, Jaffe ES, Diebold J, et at. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997[J]. J Clin Oncol, 1999, 17(12): 3835-3849.
  • 5Sinnberg T, Lasithiotakis K, Niessner H, et al. Inhibition of PI3K- AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide [J]. J Invest Dermatol, 2009, 129 (6): 1500-1515.
  • 6Johnson SM, Gulhati P, Rampy BA, et al. Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer [J]. J Am Coil Surg, 2010, 210 (5): 767-778.
  • 7Grunt TW, Mariani GL. Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling [J].Curr Cancer Drug Targets, 2013, 13(2) : 188-204.
  • 8Chen J, Zhao KN, Li R, et al. Activation of PI3FUAkt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer [J]. Curr Med Chem, 2014, 21(26): 3070-3080.
  • 9Milosevic Z, Pesic M, Stankovic T, et al. Targeting RAS-MAPK- ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma [J]. Transl Res, 2014, 164(5 ) : 411-423.
  • 10Sander S, Rajewsky K. Burkitt lymphomagenesis linked to myc plus PI3K in germinal center B cells[J]. Oncotarget, 2012, 3(10) : 1066- 1067.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部